the choice of outcome parameters and need for distinct
play

The choice of outcome parameters and need for distinct assessment tools with regard to the different disease stages in Alzheimer s disease Iva Holmerov Czech Alzheimer Society Alzheimer Europe Patient organisation view Czech

0 downloads 3 Views 729 KB Size Report
  1. The choice of outcome parameters and need for distinct assessment tools with regard to the different disease stages in Alzheimer ’s disease… Iva Holmerová Czech Alzheimer Society Alzheimer Europe

  2. Patient organisation view Czech Alzheimer Society Alzheimer Europe

  3. Czech Republic (since 1993) • Population 10,5 mil. (6 % foreigners) • Life Expectancy (males 75,2, females 81,1) • Unemployment 7,4 % (end of July 2014) • Economic growth 2,7% (2nd Q of 2014) • Spending on health (7,5% of GDP) • 140 ths. persons living with dementia

  4. OSKAR FISCHER 1876- 1942 (Slaný - KZ Teresienstadt) Worked in the Department of Pathology, Psychiatric Department, Charles University in Prague 1907 – pathological findings in 12 cases of „senile“dementia and 16 Oskar Fischer, 1876 - 1942 controls

  5. Oskar Fischer´s article

  6. Disease burden H.Brodaty (Paris Alzheimer, 2008): - 19th century – infections - 20th century – cardiovascular and oncological diseases - 21st century – neurodegeneration And yet: 1/20 of research support compared to oncological or cardiovascular diseases

  7. DEMENTIA- Research focus on: • Primary prevention • Disease modification Pre-clinical stages: GAP between the precise diagnosis and no causal or d.m. therapy Drug trials – hope to those (brave) who decide to know more Ethical considerations (surveillance) and research, culture, anthropology… • Symptomatic improvement • „Stand alone“ (?) symptoms (agitation, agression…)

  8. ABC - Dementia syndrome • Activities of Daily Living • BPSD • Cognition

  9. Strategy P-PA-IA – acronym of three stages and changing needs of PwD (strategy of the Czech Alzheimer Society) 1 (P) 2 (PA) 3 (IA) stadium Psychology potřeby Individualizovaná Support asistence Counselling Diagnosis Meaningul activities Disclosure Care Therapy Support Individualized Legal issues Caregivers approach Supervision Nursing care Nefarmakologické metody Palliative care Paliativní péče

  10. Complexity of the dementia syndrome • Life history, experience, • Values, priorities • Current tasks of life • Disease pathology (proteins – A-beta, tau) • Localisation of pathology • Different leading symptoms – h.memory, visuospatial, verbal, frontal … • Progression of the disease • Environment and support, people around us, complexity of the external and changing world • Different cultures…. • „psychosocial context“ and interventions

  11. Dementia stage of AD research focus: • Cognitive endpoint (objective tests) • Functional endpoint (IADLs) • Global endpoint (global assessment) • …… other? – separate and integrated • BPSD as „stand alone“ • ??? – resistiveness to care (Volicer)

  12. Psychosocial interventions Positive effects are demonstrated on patient • cognition (Olazaran et al.,2010) • behaviour (Olazaran et al.,2010) • family carer mood (Vernooij-Dassen, Draskovic, et al., 2011) • they reduce costs by delaying institutionalization (Spijker et al., 2008). (Vernooij -Dassen & Moniz-Cook, 2014)

  13. Clinical „pictures“ - complexity • Different types of dementia • Different manifestations of Alzheimer´s disease • Variability: personality, context and conditions, disease progression…. • Do we need mor appropriate and detailed descriptions of „clinical pictures“ of dementia? Follow up along the progression trajectory? • Dementia as a „novel“ syndrome (20th century…) • God is in the detail (A.Warburg) • Morelli case in art (C. Ginzburg)

  14. Suggestions: • Ethical considerations – on a higher level than currently • Anthropological issues/cultural differences • Social aspects – stigma, occupation, insurance… • Effects of psychosocial aspects and interventions • Context of life, care and therapy… Should be considered also in drug trials Is it possible to separate drug, clinical and psychosocial research on dementia?

  15. CELLO - Centrum pro studium dlouhověkosti a dlouhodobé péče Fakulta humanitních studií Univerzity Karlovy Gerontologické centrum 18200 Praha 8 – Kobylisy Šimůnkova 1600 email: iva.holmerova@gerontocentrum.cz www.cello-ilc.cz

Recommend Documents


workshop on alzheimer s disease 24 25 november 2014
Workshop on Alzheimers disease, 24-25

The choice of outcome parameters and need for distinct assessment tools with

the choice of effect measure for binary outcomes
The Choice of Effect Measure for Binary

The Choice of Effect Measure for Binary Outcomes: Introducing Counterfactual

hi histor orical al outcome p parameters u used ed in pbc
Hi Histor orical al outcome p

Hi Histor orical al outcome p parameters u used ed in PBC and the s e

judicious choice of waveform parameters and judicious
Judicious Choice of Waveform Parameters

Judicious Choice of Waveform Parameters and Judicious Choice of Waveform

currently proposed endpoints in psc the search for
Currently proposed endpoints in PSC:

Currently proposed endpoints in PSC: the search for reliable surrogate outcome

analysis of variance and regression november 22 2007
Analysis of variance and regression

Analysis of variance and regression November 22, 2007 Parametrisations :

outcome 7 factors of america s industrial growth
Outcome: 7 Factors of Americas

Outcome: 7 Factors of Americas Industrial Growth 1. Setting the

choice theory
Choice theory Michel Bierlaire

Choice theory Michel Bierlaire michel.bierlaire@epfl.ch Transport and

computational social choice
Computational social choice

Computational social choice Combinatorial voting Lirong Xia Feb 23, 2016

dichotomies and growth function
Dichotomies and Growth Function

1 (1) tuitively, we are hoping that the number of distinct labelings is

the potential for new treatments for alzheimer s disease
The Potential for New Treatments for

The Potential for New Treatments for Alzheimers Disease: Where Are We Headed

dementia
Dementia An interprofessional

T HIS CLINICAL TRAINING INITIATIVE IS SUPPORTED BY FUNDING FROM THE A USTRALIAN

dementia and developmental disabilities supporting
Dementia and Developmental

Dementia and Developmental Disabilities: Supporting Individuals in Maintaining

moderator leah levine
MODERATOR: LEAH LEVINE Recruitment

YOUTH ENGAGEMENT IN ALZHEIMERS DISEASE ADVOCACY AND CAREGIVING PANEL

investor presentation
Investor Presentation A novel approach

Investor Presentation A novel approach to treating cognitive impairment and

heather m snyder ph d senior director medical amp
Heather M. Snyder, Ph.D. Senior

Update on Alzheimers Research for NARFE Heather M. Snyder, Ph.D. Senior

developing drugs for the treatment of alzheimer s disease
DEVELOPING DRUGS FOR THE TREATMENT OF

DEVELOPING DRUGS FOR THE TREATMENT OF ALZHEIMERS DISEASE Eric Bastings, MD

prevalence of mixed pathologies in
Prevalence of mixed pathologies in

Prevalence of mixed pathologies in dementia and movement disorders Edward B.

1
1 3 6 th leading cause of death

1 3 6 th leading cause of death across Alzheimer's all ages Disease 68%

targeting neuroinflammation the common
Targeting Neuroinflammation: The Common

Targeting Neuroinflammation: The Common Thread in Neurodegenerative Disease

5 5 2015
5/5/2015 Down syndrome, aging and

5/5/2015 Down syndrome, aging and Alzheimer's disease: Improving outcomes of

statewide services for traumatic brain injuries alzheimer
Statewide Services for Traumatic Brain

Statewide Services for Traumatic Brain Injuries, Alzheimers Disease, and